The report provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued projects.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/711828-deep-vein-thrombosis-dvt-pipeline-review-h2-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT)
- The report reviews pipeline therapeutics for Deep Vein Thrombosis (DVT) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Deep Vein Thrombosis (DVT) therapeutics and enlists all their major and minor projects
- The report assesses Deep Vein Thrombosis (DVT) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Deep Vein Thrombosis (DVT)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Deep Vein Thrombosis (DVT) Overview 7
Therapeutics Development 8
Pipeline Products for Deep Vein Thrombosis (DVT) - Overview 8
Pipeline Products for Deep Vein Thrombosis (DVT) - Comparative Analysis 9
Deep Vein Thrombosis (DVT) - Therapeutics under Development by Companies 10
Deep Vein Thrombosis (DVT) - Therapeutics under Investigation by Universities/Institutes 11
Deep Vein Thrombosis (DVT) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Deep Vein Thrombosis (DVT) - Products under Development by Companies 15
Deep Vein Thrombosis (DVT) - Products under Investigation by Universities/Institutes 16
Deep Vein Thrombosis (DVT) - Companies Involved in Therapeutics Development 17
3SBio Inc. 17
Dong-A Socio Holdings Co. Ltd. 18
F. Hoffmann-La Roche Ltd. 19
Generex Biotechnology Corporation 20
Laboratorios Farmaceuticos Rovi, S.A. 21
Pharmathen Pharmaceuticals S.A. 22
Deep Vein Thrombosis (DVT) - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
Antisense RNAi Oligonucleotide for Deep Vein Thrombosis - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
ARC-15105 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
CM-20201 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
enoxaparin sodium biosimilar - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
enoxaparin sodium biosimilar - Drug Profile 36
Access Report @ https://www.wiseguyreports.com/reports/711828-deep-vein-thrombosis-dvt-pipeline-review-h2-2016
Contact Info:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
No comments:
Post a Comment